Trung Huynh
Stock Analyst at UBS
(2.07)
# 1320
Out of 5,218 analysts
30
Total ratings
60.00%
Success rate
28.57%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Kyverna Therapeutics | Initiates Coverage On: Buy | 13 | 4.38 | 196.8% | 1 | Oct 10, 2024 | |
Cabaletta Bio | Initiates Coverage On: Buy | 10 | 2.72 | 267.65% | 1 | Oct 10, 2024 | |
Bristol-Myers Squibb | Maintains: Neutral | 50 54 | 56.61 | -4.61% | 4 | Oct 9, 2024 | |
Insmed | Maintains: Strong Buy | 78 84 | 73.74 | 13.91% | 3 | Aug 9, 2024 | |
Eli Lilly | Assumes: Strong Buy | 612 710 | 798.14 | -11.04% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 170 175 | 146.85 | 19.17% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 220 200 | 270.65 | -26.1% | 3 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 47 40 | 25.7 | 55.64% | 4 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 125 126 | 101.75 | 23.83% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 170 | 171.19 | -0.7% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 1 | Mar 23, 2021 |